Cipla Ltd (CIPLA)

Cipla Set to Release Q1FY25 Earnings - 24 Jul, 2024

Cipla is set to release its quarterly earnings for the first quarter of financial year 2024-25 (Q1FY25) on Friday, July 26, 2024. The pharma major is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year-on-year basis and net profits seeing mid-single-digit growth.

Cipla to Announce Q1FY25 Results on July 26 - 21 Jul, 2024

Cipla Ltd is set to announce its quarterly results for Q1FY25 on July 26, 2024. The stock has delivered over 40% returns in the past year. However, the company's revenue decreased by around 7%, and net profits declined by around 13% during Q3FY24 to Q4FY24.

Indian CDMOs like Cipla and Syngene are cost-effective with skilled workforce - 19 Jul, 2024

The Indian government has been offering grants and loans to boost the sector. The Biosecure Act could be a game-changer for the Indian CDMO space, but it demands significant investment in infrastructure and talent to handle the influx of projects.

Cipla Receives Rs 773.44 Crore Demand Notice from Income Tax Department - 17 Jul, 2024

The income tax department has issued a demand notice of Rs 773.44 crore to Cipla for assessment years 2015-16 to 2022-23. The company plans to appeal the orders and believes they are not tenable in law, with no expected material impact on financial or operational aspects.

Cipla Receives Additional Tax Demand of Rs 773.44 Crore - 16 Jul, 2024

Cipla Ltd has received an additional tax demand of Rs 773.44 crore from the Indian Income Tax Department for assessment years 2015-16 to 2022-23, citing rule violations including short deductions and disallowances of various expenses under the Income Tax Act Section 37(1). Cipla plans to appeal against the IT order under applicable laws.

Analysts Recommend Going Long on Cipla Ltd - 08 Jul, 2024

Cipla Ltd shows a potential bullish trend as it displays a clean breakout on the daily chart. Analysts suggest going long within the price range of 1500-1510 with an upside target of Rs 1600 and stop-loss at Rs 1460.

Cipla Aims for Increased Innovative Revenue Contribution - 05 Jul, 2024

Cipla is charting its course to increase its innovative revenue contribution to reach at least 70% of revenues. The company has allotted equity shares under the Employee Stock Option Scheme.

Cipla Collaborates with Orchid Pharma for Antibiotic Launch - 01 Jul, 2024

Cipla has partnered with Orchid Pharma to launch the antibiotic Cefepime-Enmetazobactam in India, aimed at treating complicated urinary tract infections and pneumonia. The collaboration combines Orchids innovative drug development capabilities with Ciplas extensive distribution network and market presence.

Cipla Partners with Orchid Pharma for Rapid Distribution of New Drug - 29 Jun, 2024

Cipla has partnered with Orchid Pharma to ensure widespread and rapid distribution of its new drug, Cefepime-Enmetazobactam, across India. The collaboration combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence.

Cipla Partners with Orchid Pharma; Shares Snap Losing Streak - 28 Jun, 2024

Cipla's partnership with Orchid Pharma to launch a new drug across India has enhanced its commitment to AMR stewardship. The company also snapped a seven-day losing streak after the US FDA cleared it of four violations observed during an inspection. Analysts remain hopeful that Cipla will meet margin guidance for this year.

Cipla Invests in Achira Labs; Motilal Oswal Recommends Buying - 27 Jun, 2024

Cipla is set to invest up to ₹26 crore in Achira Labs, increasing its stake to 27.27%. Meanwhile, Motilal Oswal has reiterated its buy call on Cipla with a target price of Rs 1700.

Cipla Reports Strong Q4 Results and Receives VAI Status for Patalganga Unit - 25 Jun, 2024

Cipla reported a 79% YoY jump in Q4 FY24 net profit to Rs 939.04 crore and received a Voluntary Action Indicated (VAI) status from the USFDA for its Patalganga unit. However, the USFDA also inspected Cipla's Goa manufacturing facility and found six observations documented in Form 483.